Schrodinger, Inc. Stock Price, News & Analysis

Schrödinger (SDGR) announced upcoming presentations of initial Phase 1 clinical data for SGR-1505, their investigational MALT1 inhibitor, at two major conferences. The data will be presented at the European Hematology Association Annual Congress (June 12-15, 2025, Milan) and the International Conference on Malignant Lymphoma (June 17-21, 2025, Lugano).

The Phase 1 study evaluates SGR-1505's safety, tolerability, and anti-tumor activity in patients with relapsed/refractory B-cell malignancies. The presentations will include initial safety, pharmacokinetic and pharmacodynamic data, plus preliminary efficacy data across various dosing levels. The company will host a webcast to discuss the data on June 12, 2025, at 8:00 a.m. ET.

Schrödinger (NASDAQ: SDGR) reported strong Q1 2025 financial results with total revenue of $59.6 million, up 63% year-over-year. Software revenue grew 46% to $48.8 million, while drug discovery revenue reached $10.7 million, up from $3.2 million in Q1 2024. Despite revenue growth, the company posted a net loss of $59.8 million. Software gross margin was 72%, down from 76% in Q1 2024. The company maintained its 2025 guidance, expecting software revenue growth of 10-15% and drug discovery revenue of $45-50 million. Schrödinger plans to present initial clinical data for its MALT1 inhibitor SGR-1505 in June and expects data from two other clinical trials in H2 2025. The company is also advancing its predictive toxicology initiative, expected to launch in H2 2025.

Schrödinger (NASDAQ: SDGR) announced its upcoming participation in the BofA Securities 2025 Healthcare Conference. The company's management will engage in a fireside chat scheduled for Wednesday, May 14, 2025, at 4:40 p.m. ET. Interested parties can access the live webcast through the "Investors" section of Schrödinger's website, where it will remain available for approximately 90 days after the event.

Schrödinger (SDGR) presented preclinical data for two cancer drug candidates at the AACR Annual Meeting 2025. The first candidate, SGR-3515, a Wee1/Myt1 co-inhibitor, showed improved anti-tumor activity compared to existing monotherapy inhibitors, with optimized dosing schedules allowing efficacy preservation while minimizing side effects. Initial Phase 1 trial data for SGR-3515 in advanced solid tumors is expected in H2 2025.

The second candidate, SGR-4174, a novel SOS1 inhibitor targeting KRAS mutations, demonstrated high selectivity and strong tumor growth inhibition both as monotherapy and in combination with MEK or KRAS inhibitors. The company also presented data on a new computational method for predicting responses to Wee1-based drug combinations, particularly in head and neck cancers.

Schrödinger (SDGR) has scheduled the release of its first quarter 2025 financial results for Wednesday, May 7, 2025, following the close of financial markets. The company will hold a conference call and webcast at 4:30 p.m. ET on the same day. Investors can access the live webcast through the company's website's 'Investors' section, where it will remain available for approximately 90 days after the event.

Schrödinger (Nasdaq: SDGR) has announced new inducement grants to seven newly hired employees on April 16, 2025. The grants include:

- A non-statutory stock option to purchase 3,300 shares (exercise price: $25.21 per share) granted to one employee
- Restricted stock units (RSUs) for 12,866 shares granted to six employees

The grants were made under the company's 2021 Inducement Equity Incentive Plan. The stock option has a ten-year term with 25% vesting after 12 months and the remainder vesting monthly over 36 months. RSUs vest over four years, with 25% vesting after 12 months and the remaining vesting yearly over three years.

Schrödinger (SDGR) has expressed strong support for the FDA's initiative to reduce animal testing requirements in drug development through computational approaches. The company's platform enables accurate in silico predictions for both small molecules and biologics across biological targets.

The company is developing a predictive toxicology solution, funded by the Bill & Melinda Gates Foundation, aimed at improving drug candidate properties and reducing development risks. This initiative focuses on predicting toxicology risks early in drug discovery, particularly regarding off-target protein binding.

Schrödinger has already developed computational models for key off-targets, including recent advances in characterizing safety-related proteins like hERG and cytochrome P450 enzymes. The company plans to launch its predictive toxicology solution in the second half of 2025. Their platform currently includes solutions for predicting protein aggregation in biologics and binding affinity evaluation.

Schrödinger (SDGR) announced upcoming presentations of preclinical data for two investigational cancer treatments at the AACR Annual Meeting 2025 in Chicago. The company will present data on SGR-3515, a Wee1/Myt1 inhibitor, showing improved therapeutic results through optimized intermittent dosing in preclinical oncology models. A Phase 1 clinical trial for SGR-3515 is ongoing, with initial data expected in H2 2025.

Additionally, SDGR will present findings on a machine learning model that predicts drug combination responses with Wee1 inhibitors. The company will also showcase the first preclinical data for SGR-4174, their SOS1 inhibitor targeting KRAS-driven cancers. The data suggests SGR-4174 has a differentiated profile supporting its development for KRAS mutant cancers and rare diseases arising from KRAS pathway mutations.

Schrödinger (SDGR) has announced new inducement grants for recently hired employees. The company granted a non-statutory stock option to purchase 1,575 shares to one employee and restricted stock units (RSUs) for 6,943 shares to seven employees.

The stock option, priced at $22.90 per share, has a ten-year term and vests over four years, with 25% vesting after 12 months and the remainder vesting monthly over the following 36 months. The RSUs also vest over four years, with 25% vesting after the first year and the remaining portions vesting annually over three years.

These grants were made under the company's 2021 Inducement Equity Incentive Plan and were approved by the compensation committee in accordance with Nasdaq Listing Rule 5635(c)(4).